424 results on '"Munakata, Wataru"'
Search Results
2. Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy
3. Heterogeneity or change in cell of origin in diffuse large B-cell lymphomas determined using hans algorithm
4. Clinicopathological differences between T-lymphoblastic leukemia/lymphoma, early T-precursor lymphoblastic leukemia/lymphoma, and mixed-phenotype acute leukemia with T lineage: An analysis of 41 adult cases
5. Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies
6. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma
7. Effects of body compositions on the associations between ferritin and diabetes parameters among Japanese community dwellers
8. Pathogenesis of Gastrointestinal Follicular Lymphomas: Consideration Based on Histopathology and Endoscopic Findings
9. Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia–lymphoma
10. Interim PET‐guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced‐stage classic Hodgkin lymphoma (JCOG1305).
11. Usefulness of hematopoietic progenitor cell monitoring to predict autologous peripheral blood stem cell harvest timing: A single-center retrospective study
12. Adult T-Cell Leukemia-Lymphoma
13. The Association between Gut Microbiota and Depression in the Japanese Population
14. An update on the developments in the treatment of adult T-cell leukemia–lymphoma: current knowledge and future perspective
15. P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE
16. P1520: PROGNOSTIC IMPACT OF FEBRILE NEUTROPENIA AND DOSE INTENSITY OF R-CHOP THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA, A SUPPLEMENTARY ANALYSIS OF JCOG0601
17. New Agents of Adult T-cell Leukemia/Lymphoma (ATL)
18. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma
19. Clinicopathological characteristics of diffuse large B-cell lymphoma involving small and large intestines: an analysis of 126 patients
20. Mucosa-associated lymphoid tissue lymphoma with t(11;18)(q21;q21) translocation: long-term follow-up results
21. Comparison of clinicopathologic characteristics of gastric follicular lymphomas and duodenal follicular lymphomas
22. Adult T-Cell Leukemia-Lymphoma
23. Multiple myeloma with IGH-FGFR3 rearrangement progressing as testicular plasmacytoma during carfilzomib treatment
24. CD3+ CD56+ EBER1+ atypical extraosseous plasmacytoma of the nasal cavity
25. Variegated RHOA mutations in adult T-cell leukemia/lymphoma
26. Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
27. Diagnostic clues of BCL2-negative, faint, or controversial follicular lymphomas: A study of 103 cases
28. Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies
29. Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)
30. Marked erythroblastosis in myelodysplastic syndrome induced by gastric hemorrhaging
31. Distribution of malignant lymphomas in the anterior mediastinum: a single-institution study of 76 cases in Japan, 1997–2016
32. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia
33. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma
34. Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment
35. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era
36. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers
37. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy
38. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma
39. Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma
40. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma
41. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies
42. SY08-2 The development of BCR signaling pathway-targeted therapy for B-cell malignancies
43. CD3-and CD20-negative extramedullary non-Hodgkin leukemia/lymphoma: a histopathological study of 118 cases
44. Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia
45. The outcome of watchful waiting in patients with previously treated follicular lymphoma
46. Successful full-dose DeVIC therapy in a patient with advanced-stage extranodal natural killer/T-cell lymphoma refractory to l-asparaginase
47. A Case of Diffuse Large B-cell Lymphoma with Portal Vein, Splenic Vein, and Superior Mesenteric Vein Tumor Embolization Diagnosed by Percutaneous Transhepatic Portal Vein Biopsy
48. The role of surveillance computed tomography in patients with follicular lymphoma
49. Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemiatwo -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia
50. Diagnostic utility and prognostic significance of the Ki‐67 labeling index in diffuse large B‐cell lymphoma transformed from follicular lymphoma: a study of 76 patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.